Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
Status:
Recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well olaparib with or without atezolizumab work in
treating patients with non-HER2-positive breast cancer that has spread from its original site
of growth to nearby tissues or lymph nodes and is not amenable to surgical resection (locally
advanced unresectable) or has spread to other places in the body (metastatic). Olaparib is an
inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes
damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing
them to die. PARP inhibitors are a type of targeted therapy. Immunotherapy with monoclonal
antibodies, such as atezolizumab, may help the body's immune system attack the tumor, and may
interfere with the ability of tumor cells to grow and spread. It is not known whether giving
olaparib with or without atezolizumab will work better in patients with non-HER2-positive
breast cancer.